Diffuse alveolar haemorrhage as a rare complication of antiphospholipid syndrome | Zendy

Seth Ishith | Zendy; Bhagavata Srinivasan Shyam Prakaash | Zendy; Bulloch Gabriella | Zendy; Yi Dong Seok | Zendy; Frankel Anthony | Zendy; Hsu Kelvin | Zendy; Passam Freda | Zendy; Garsia Roger | Zendy; Corte Tamera J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Diffuse alveolar haemorrhage as a rare complication of antiphospholipid syndrome

Author(s) -

Seth Ishith,

Bhagavata Srinivasan Shyam Prakaash,

Bulloch Gabriella,

Yi Dong Seok,

Frankel Anthony,

Hsu Kelvin,

Passam Freda,

Garsia Roger,

Corte Tamera J.

Publication year - 2022

Publication title -

respirology case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.304

H-Index - 9

ISSN - 2051-3380

DOI - 10.1002/rcr2.948

Subject(s) - medicine , diffuse alveolar hemorrhage , complication , rituximab , antiphospholipid syndrome , methylprednisolone , cyclophosphamide , intravenous immunoglobulins , surgery , chemotherapy , thrombosis , lymphoma , antibody , immunology

Diffuse alveolar haemorrhage (DAH) is a rare complication of antiphospholipid syndrome. With a mortality rate of 46%, early diagnosis and management remain an ongoing challenge. Case reports are limited, and management guidelines are not yet definitive. In this case report, we present a 43‐year‐old male with DAH who required high‐dose oral steroids, intravenous methylprednisolone cyclophosphamide and rituximab over 18 months to control life‐threatening episodes of pulmonary bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research